3/5/15 Options Express
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from this strong interest, the research firm said. In Deceber,Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
Could This Clinical-Stage Biotech Stock Soar in April?
By Motley Fool, March 12, 2015, 08:59:01 AM EDT
ADXS: Positive Phase I/II Data Reported on ADXS-HPV
3/17/15We maintain our Outperform rating for ADXS and raise our target to $18.00 per share from previous $15.00 per share based on the recent clinical achievements.
The Fly On The Wall
Breaking News Feed
( KITE )
Buy Opportunity Before ASCO Conference May 2015 - Cowen Outperform Rating
either is great but wondering
anyone with real answers?
Business Wire 4/8/15
CyberArk Announces Release Date of First Quarter 2015 Financial Results
CyberArk Software Ltd. (CYBR), the company that protects organizations from cyber attacks that have made their way inside the network perimeter, today announced that it will report its first quarter 2015 financial results after the U.S. financial markets close on Thursday, May 7, 2015.